Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

C
PT-026
CAN MODEL BASED APPROACHES ACCURATELY IDENTIFY BIO(IN)EQUIVALENCE OF TOPICAL CLOTRIMAZOLE PRODUCTS?

Favorite
LB-009
CANNABIDIOL INCREASES EXPOSURE OF TACROLIMUS IN HEALTHY VOLUNTEERS.

Favorite
OAII-004
CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.

Favorite
PT-013
CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.

Favorite
PII-016
CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Favorite
OAI-001
CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Favorite
PII-007
CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Favorite
TIP-004
CHARACTERIZATION OF LABETALOL IN PREGNANCY (THE CLIP STUDY).

Favorite
PII-017
CHARACTERIZING CELLULAR KINETICS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

Favorite
PII-101
CHARACTERIZING EXPOSURE-RESPONSE RELATIONSHIPS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

Favorite
PII-018
CLINICAL DOSE PREDICTION FOR CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPIES USING A MULTI-SCALE QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) PLATFORM MODEL

Favorite
PII-102
CLINICAL DRUG-DRUG INTERACTION STUDY INTEGRATED WITH PBPK MODELLING PROVIDES INSIGHTS INTO THE INDUCTION POTENTIAL OF MAVACAMTEN ACROSS CYP2C19 PHENOTYPES.

Favorite
PII-197
CLINICAL EFFECTS OF MEDICAL CANNABIS FOR POST-TRAUMATIC STRESS DISORDER (PTSD) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS - A RETROSPECTIVE COHORT STUDY BASED ON MINNESOTA'S MEDICAL CANNABIS REGISTRY.

Favorite
PII-049
CLINICAL PHARMACOKINETICS OF ABBV-400, A NOVEL C-MET-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS.

Favorite
PII-103
CLINICAL PHARMACOLOGY CHARACTERIZATION OF BLINATUMOMAB FROM SUBCUTANEOUS (SC) DOSING IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Favorite
PII-180
CLINICAL PHARMACOLOGY CONSIDERATIONS FOR FIRST-IN-HUMAN CLINICAL TRIALS FOR ENZYME REPLACEMENT THERAPY

Favorite
PII-198
CLINICAL PHARMACOLOGY CONSIDERATIONS IN EXTRAPOLATION OF EFFICACY AND SAFETY FROM ADULTS TO PEDIATRICS - LESSONS LEARNED FROM PEDIATRIC PROGRAMS OF DIRECT ORAL ANTICOAGULANTS.

Favorite
PII-050
CLINICAL PHARMACOLOGY OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR

Favorite
PII-104
CLINICAL TRIAL SIMULATIONS FOR OPTIMAL SAMPLING TO ASSESS DURABILITY OF PCV IMMUNE RESPONSE IN ADULTS.

Favorite
PII-105
COMBINED PARENT AND PAYLOAD POPULATION PHARMACOKINETIC MODELING TO SUPPORT DOSE RECOMMENDATION OF THE NOVEL ANTI-TROP-2 ANTIBODY-DRUG CONJUGATE (ADC) SHR-A1921.

Favorite
PII-106
COMPARATIVE PHARMACOKINETICS AND SAFETY OF DWJ1451 AND CO-ADMINISTRATION OF OLMESARTAN MEDOXOMIL/AMLODIPINE/ROSUVASTATIN AND EZETIMIBE TABLETS IN HEALTHY KOREAN SUBJECTS

Favorite
CT-010
COMPARATIVE PHARMACOKINETICS AND SAFETY OF DWJ1451 AND CO-ADMINISTRATION OF OLMESARTAN MEDOXOMIL/AMLODIPINE/ROSUVASTATIN AND EZETIMIBE TABLETS IN HEALTHY KOREAN SUBJECTS

Favorite
PII-107
COMPARATIVE PHARMACOKINETICS/PHARMACODYNAMICS OF FIXED-DOSE COMBINATION OF RABEPRAZOLE/MAGNESIUM OXIDE 10/350MG (DHNP-2001A) TO THE CONVENTIONAL ENTERIC-COATED RABEPRAZOLE 10MG

Favorite
PII-026
COMPARISON OF CHANGES IN PUPIL DIAMETER AND HYPERCAPNIC VENTILATION FOR OXYCODONE AND PSYCHOTROPIC DRUGS ADMINISTERED ALONE OR IN COMBINATION

Favorite
PWI-001
COMPARISON OF METHODS OF FIRST-IN-HUMAN DOSE PREDICTION FOR ADENO-ASSOCIATED VIRUS-MEDIATED GENE THERAPIES IN FABRY DISEASE

Favorite
PII-019
COMPARISON OF METHODS OF FIRST-IN-HUMAN DOSE PREDICTION FOR ADENO-ASSOCIATED VIRUS-MEDIATED GENE THERAPIES IN FABRY DISEASE

Favorite
PT-022
COMPUTATIONAL SYSTEMS PHARMACOLOGY OF PYRROLOBENZODIAZEPINE-BASED ANTIBODY-DRUG CONJUGATES

Favorite
PII-008
C-PEPTIDE DISEASE PROGRESSION MODEL IN INDIVIDUALS WITH NEW-ONSET TYPE 1 DIABETES

Favorite